Prothena Corp Public (PRTA) Assets Average (2013 - 2026)
Prothena Corp Public (PRTA) posted quarterly Assets Average of $338.3 million for Q1 2026, down 35.09% year-over-year from $521.2 million in Q1 2025, and little changed quarter-over-quarter from $339.7 million in Q4 2025.
Prothena Corp Public (PRTA) Assets Average (2013 - 2026) Analysis & Trends
Prothena Corp Public's Assets Average history runs 14 years deep, the most recent figure standing at $338.3 million for Q1 2026.
- In Q1 2026, Assets Average fell 35.09% year-over-year to $338.3 million; the TTM figure through Mar 2026 stood at $338.3 million (down 35.09% YoY), while the FY2025 annual figure was $437.0 million, down 29.72% from the prior year.
- Assets Average for Q1 2026 stood at $338.3 million, roughly flat from $339.7 million in the prior quarter.
- The five-year high for Assets Average was $749.8 million in Q1 2023, with the low at $338.3 million in Q1 2026.
- The 5-year median for Assets Average is $595.4 million (2022), against an average of $577.3 million.
- The sharpest annual moves came in 2022 and 2025: Assets Average soared 67.08% in 2022, then slumped 40.52% in 2025.
- Prothena Corp Public's Assets Average stood at $656.2 million in 2022, then gained by 9.97% to $721.7 million in 2023, then dropped by 20.85% to $571.2 million in 2024, then plunged by 40.52% to $339.7 million in 2025, then dropped by 0.4% to $338.3 million in 2026.
- Business Quant data shows PRTA's Assets Average at $338.3 million in Q1 2026, $339.7 million in Q4 2025, and $375.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 326.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 326.24 Mn |
| Mar 31, 2026 | 338.35 Mn |
| Dec 31, 2025 | 339.72 Mn |
| Sep 30, 2025 | 375.85 Mn |
| Jun 30, 2025 | 447.20 Mn |
| Mar 31, 2025 | 521.22 Mn |
| Dec 31, 2024 | 571.18 Mn |
| Sep 30, 2024 | 620.41 Mn |
| Jun 30, 2024 | 634.38 Mn |
| Mar 31, 2024 | 659.79 Mn |
| Dec 31, 2023 | 721.65 Mn |
| Sep 30, 2023 | 733.78 Mn |
| Jun 30, 2023 | 731.12 Mn |
| Mar 31, 2023 | 749.81 Mn |
| Dec 31, 2022 | 656.24 Mn |
| Sep 30, 2022 | 552.01 Mn |
| Jun 30, 2022 | 565.50 Mn |
| Mar 31, 2022 | 595.39 Mn |
| Dec 31, 2021 | 621.04 Mn |
| Sep 30, 2021 | 534.54 Mn |